Cue Biopharma, Inc. (CUE): Shareholders' Equity
$26.43M
As of 2025-12-31
$2.31M
As of 2026-06-30
-26.2%
3-year compound annual growth
-19.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.43M | +51.0% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $17.50M | -52.8% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $37.09M | -43.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $65.68M | +0.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $65.49M | -17.0% | 2023-03-21, Balance as of period end |
| 2020-12-31 | $78.91M | +44.6% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $54.58M | +60.7% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $33.97M | -44.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $61.61M | n/a | 2019-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $26.43M | +51.0% |
| Celularity Inc (CELU) | 2025-12-31 | -$38.06M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $306.13M | -28.6% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$108.50M | n/m |
| Verastem, Inc. (VSTM) | 2025-12-31 | $57.20M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $115.40M | -41.0% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $25.45M | n/m |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗